Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction
- 1 March 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (5) , 1605-1612
- https://doi.org/10.1158/1078-0432.ccr-0610-3
Abstract
Purpose: Inconsistent reports on the detection of melanoma cells in peripheral blood by reverse transcriptase-PCR (RT-PCR) have resulted in uncertainty on the prognostic value of circulating melanoma cells. Experimental Design: We developed real-time RT-PCR assays for quantitation of tyrosinase, MelanA/MART1, and gp100 and for porphobilinogen deaminase housekeeping gene. Melanoma tissue (n = 18), peripheral blood samples from healthy donors (n = 21), and patients with cutaneous (n = 122) and uveal (n = 64) melanoma from our institution were analyzed. For quality control, an additional 251 samples from ongoing multicenter studies were compared with in-house samples. Results: Tyrosinase was not detected in healthy donor blood samples. For the two other markers, cutoff values had to be defined to distinct patient samples from controls. Patients with stage IV uveal and cutaneous melanoma expressed all three markers more frequently and at higher levels in peripheral blood as compared with earlier stages. The variation of expression was 4 logs and correlated with tumor load and serum lactate dehydrogenase. In 2 of 3 uveal melanoma patients, detection of circulating tumor cells preceded the development of liver metastases. The diagnostic sensitivity was optimal in blood samples containing >0.1pg/μl porphobilinogen deaminase (95.7% of in-house samples and 57.4% of multicenter samples). Conclusions: Real-time RT-PCR is able to quantitatively define the quality of a sample and provides quantitative data for melanoma markers. Disparities in the results of previous studies may be attributable to undetected differences in sample quality. The prognostic relevance of this assay is currently under evaluation in several prospective randomized trials.Keywords
This publication has 37 references indexed in Scilit:
- Comparison of the RNA-amplification based methods RT–PCR and NASBA for the detection of circulating tumour cellsBritish Journal of Cancer, 2002
- European Proficiency Testing Program for Molecular Detection and Quantitation of Hepatitis B Virus DNAJournal of Clinical Microbiology, 2001
- MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progressionMelanoma Research, 2001
- Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thicknessBritish Journal of Dermatology, 2001
- Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.Oncology Reports, 2001
- Quantitative analysis of tyrosinase and tyrosinase-related protein-2 mRNA from melanoma cells in blood by real-time polymerase chain reactionMelanoma Research, 2000
- Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1997
- Polymerase chain reaction detection of circulating tumour cellsMelanoma Research, 1997
- Hematogenous Spread of Malignant Melanoma Cells in Different Stages of DiseaseJournal of Investigative Dermatology, 1993
- Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reactionThe Lancet, 1991